NCT01411735

Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Wake Forest University · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

BACKGROUND: Exercise intolerance is the primary symptom in older patients with heart failure and preserved ejection fraction (HFPEF), however little is known regarding its mechanisms and therapy. METHODS: 71 elderly stable, compensated HFPEF patients (age 70+1 years; 80% women) with controlled blood pressure were randomized into a 12 month follow-up (FU) double-blind trial of enalapril 20 mg per day (E) vs. placebo (P). Assessments included: peak exercise oxygen consumption (VO2); six-minute walk test; Minnesota Living with HF Questionnaire (MLHF); MRI; Doppler-echocardiography; and vascular ultrasound.

Conditions

• Heart Failure With Preserved Ejection Fraction
• Heart Failure, Congestive

Interventions

Type	Name	Description
DRUG	Enalapril	2.5mg titrated up to 10mg twice daily
DRUG	placebo	2.5mg titrated up to 10mg twice daily.

Timeline

• Start date: 2003-07-01
• Primary completion: 2004-06-01
• Completion: 2008-07-01
• First posted: 2011-08-08
• Last updated: 2017-11-06